Schuster, Eugene F. http://orcid.org/0000-0001-5076-2810
Lopez-Knowles, Elena
Alataki, Anastasia
Zabaglo, Lila
Folkerd, Elizabeth
Evans, David
Sidhu, Kally
Cheang, Maggie Chon U.
Tovey, Holly
Salto-Tellez, Manuel
Maxwell, Perry
Robertson, John
Smith, Ian
Bliss, Judith M.
Dowsett, Mitch http://orcid.org/0000-0003-4122-744X
Funding for this research was provided by:
Breast Cancer Now
Arthur Foundation
Breast Cancer Now
Cancer Research UK
DH | National Institute for Health Research
Article History
Received: 14 June 2022
Accepted: 15 June 2023
First Online: 7 July 2023
Competing interests
: M.D. reports consultancy for Astrazeneca, the ICR Rewards for Inventors Scheme for abiraterone. J.M.B. reports grants from Cancer Research UK, during the conduct of the study; grants from Medivation; grants and non-financial support from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, and Roche, outside the submitted work. M.S.T. is a scientific advisor to Mindpeak and Sonrai Analytics, and has received honoraria recently from BMS, MSD, Roche, Sanofi and Incyte. He has received grant support from Phillips, Roche, MSD and Akoya. None of these disclosures are related to this work. J.F.R.R. has received consulting fees from, and has performed contracted research on behalf of, AstraZeneca, Bayer, Novartis and Oncimmune; has given expert testimony for AstraZeneca; and holds stock with Oncimmune. M.C.U.C. has a patent for Breast Cancer Classifier: US Patent No. 9,631,239 (Method of classifying a breast cancer instrinsic subtype) with royalties paid and receive research funding from NanoString Technologies and veracyte advisory role. M.D., E.F.S. and M.C.U.C. have patent-pending (PCT/EP2021/07368; Treatment response predictive method) for predictive CDK4/6 inhibitor sensitivity assay. All other authors declare no competing interests.